Gatien Moriceau

5.9k total citations · 3 hit papers
25 papers, 2.8k citations indexed

About

Gatien Moriceau is a scholar working on Molecular Biology, Oncology and Computational Theory and Mathematics. According to data from OpenAlex, Gatien Moriceau has authored 25 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 14 papers in Oncology and 4 papers in Computational Theory and Mathematics. Recurrent topics in Gatien Moriceau's work include Melanoma and MAPK Pathways (15 papers), Cutaneous Melanoma Detection and Management (5 papers) and Bone health and treatments (4 papers). Gatien Moriceau is often cited by papers focused on Melanoma and MAPK Pathways (15 papers), Cutaneous Melanoma Detection and Management (5 papers) and Bone health and treatments (4 papers). Gatien Moriceau collaborates with scholars based in United States, France and Australia. Gatien Moriceau's co-authors include Roger S. Lo, Antoni Ribas, Xiangju Kong, Hubing Shi, Jeffrey A. Sosman, Kimberly B. Dahlman, Aayoung Hong, Willy Hugo, Richard C. Koya and Douglas B. Johnson and has published in prestigious journals such as Cell, Nature Medicine and Nature Communications.

In The Last Decade

Gatien Moriceau

23 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

2013 715 citations Hubing Shi, Willy Hugo et al. Cancer Discovery profile →
Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance

2012 470 citations Hubing Shi, Gatien Moriceau et al. Nature Communications profile →
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

2015 412 citations Willy Hugo, Hubing Shi et al. Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gatien Moriceau United States	21	2.2k	1.5k	412	406	395	25	2.8k
Nathalie Dhomen United Kingdom	19	2.2k 1.0×	1.6k 1.1×	474 1.2×	585 1.4×	318 0.8×	34	3.2k
Kimberly B. Dahlman United States	21	2.3k 1.1×	1.7k 1.1×	451 1.1×	575 1.4×	401 1.0×	38	3.2k
Kim H.T. Paraiso United States	23	1.9k 0.9×	954 0.6×	589 1.4×	368 0.9×	251 0.6×	28	2.5k
Hooman Sazegar United States	7	1.7k 0.8×	1.2k 0.8×	326 0.8×	229 0.6×	328 0.8×	7	2.1k
Ayana Sawai United States	9	2.7k 1.2×	1.1k 0.7×	238 0.6×	335 0.8×	276 0.7×	10	3.3k
Aayoung Hong United States	9	1.5k 0.7×	1.0k 0.7×	301 0.7×	250 0.6×	273 0.7×	11	1.8k
Peter F. Lebowitz United States	24	2.3k 1.1×	1.8k 1.2×	141 0.3×	422 1.0×	274 0.7×	40	3.2k
Piro Lito United States	14	2.0k 0.9×	1.3k 0.9×	166 0.4×	354 0.9×	204 0.5×	30	2.7k
Therese M. Becker Australia	31	1.5k 0.7×	1.3k 0.9×	274 0.7×	752 1.9×	129 0.3×	89	2.6k

Countries citing papers authored by Gatien Moriceau

Since Specialization

Citations

This map shows the geographic impact of Gatien Moriceau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gatien Moriceau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gatien Moriceau more than expected).

Fields of papers citing papers by Gatien Moriceau

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gatien Moriceau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gatien Moriceau. The network helps show where Gatien Moriceau may publish in the future.

Co-authorship network of co-authors of Gatien Moriceau

This figure shows the co-authorship network connecting the top 25 collaborators of Gatien Moriceau. A scholar is included among the top collaborators of Gatien Moriceau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gatien Moriceau. Gatien Moriceau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Mingming, Shangfeng Yang, Zhentao Yang, et al.. (2025). Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors. Immunity. 58(11). 2864–2877.e9.

Liu, Sixue, Shirley H. Lomeli, Yan Wang, et al.. (2023). Multi-organ landscape of therapy-resistant melanoma. Nature Medicine. 29(5). 1123–1134. 20 indexed citations

Zhang, Xiao, Sixue Liu, Shirley H. Lomeli, et al.. (2023). Blocking Genomic Instability Prevents Acquired Resistance to MAPK Inhibitor Therapy in Melanoma. Cancer Discovery. 13(4). 880–909. 53 indexed citations

Yang, Zhentao, Sixue Liu, Weixian Deng, et al.. (2022). Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance. Cancer Discovery. 12(8). 1942–1959. 32 indexed citations

Ablain, Julien, Sixue Liu, Gatien Moriceau, Roger S. Lo, & Leonard I. Zon. (2020). SPRED1 deletion confers resistance to MAPK inhibition in melanoma. The Journal of Experimental Medicine. 218(3). 21 indexed citations

Song, Chunying, Marco Piva, Lu Sun, et al.. (2017). Recurrent Tumor Cell–Intrinsic and –Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation. Cancer Discovery. 7(11). 1248–1265. 109 indexed citations

Hong, Aayoung, Gatien Moriceau, Lu Sun, et al.. (2017). Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma. Cancer Discovery. 8(1). 74–93. 72 indexed citations

Hernandez‐Davies, Jenny E., Thai Q. Tran, Michael A. Reid, et al.. (2015). Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. Journal of Translational Medicine. 13(1). 210–210. 91 indexed citations

Hugo, Willy, Hubing Shi, Lu Sun, et al.. (2015). Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance. Cell. 162(6). 1271–1285. 412 indexed citations breakdown →

10.

Moriceau, Gatien, Benjamin Ory, Céline Charrier, et al.. (2014). Imatinib Mesylate Exerts Anti-Proliferative Effects on Osteosarcoma Cells and Inhibits the Tumour Growth in Immunocompetent Murine Models. PLoS ONE. 9(3). e90795–e90795. 40 indexed citations

11.

Shi, Hubing, Aayoung Hong, Xiangju Kong, et al.. (2013). A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition. Cancer Discovery. 4(1). 69–79. 133 indexed citations

12.

Shi, Hubing, Willy Hugo, Xiangju Kong, et al.. (2013). Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy. Cancer Discovery. 4(1). 80–93. 715 indexed citations breakdown →

13.

Shi, Hubing, Gatien Moriceau, Xiangju Kong, et al.. (2012). Preexisting MEK1 Exon 3 Mutations in V600E/K BRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors. Cancer Discovery. 2(5). 414–424. 75 indexed citations

14.

Moriceau, Gatien, Dominique Heymann, M Decurtins, et al.. (2012). Pharmacological blocking of the osteoclastic biocorrosion of surgical stainless steel in vitro. Journal of Biomedical Materials Research Part A. 101A(4). 991–997. 2 indexed citations

15.

Shi, Hubing, Gatien Moriceau, Xiangju Kong, et al.. (2012). Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications. 3(1). 724–724. 470 indexed citations breakdown →

16.

Moriceau, Gatien, Anke J. Roelofs, Régis Brion, et al.. (2011). Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth. Cancer. 118(3). 750–760. 21 indexed citations

17.

Moriceau, Gatien, Benjamin Ory, Laura Mitrofan, et al.. (2010). Zoledronic Acid Potentiates mTOR Inhibition and Abolishes the Resistance of Osteosarcoma Cells to RAD001 (Everolimus): Pivotal Role of the Prenylation Process. Cancer Research. 70(24). 10329–10339. 74 indexed citations

18.

Moriceau, Gatien, Benjamin Ory, Franck Verrecchia, et al.. (2010). Therapeutic Approach of Primary Bone Tumours by Bisphosphonates. Current Pharmaceutical Design. 16(27). 2981–2987. 30 indexed citations

19.

Ory, Benjamin, Gatien Moriceau, Valérie Trichet, et al.. (2008). Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. Journal of Cellular and Molecular Medicine. 12(3). 928–941. 27 indexed citations

20.

Ory, Benjamin, Gatien Moriceau, Françoise Rédiní, & Dominique Heymann. (2007). mTOR Inhibitors (Rapamycin and its Derivatives) and Nitrogen Containing Bisphosphonates: Bi-Functional Compounds for the Treatment of Bone Tumours. Current Medicinal Chemistry. 14(13). 1381–1387. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact